(Q33872811)

29 July 2017

Thalidomide in patients with cachexia due to terminal cancer: preliminary report (English)

1 reference

29 July 2017

0 references

E Bruera

1

1 reference

29 July 2017

C M Neumann

2

1 reference

29 July 2017

E Pituskin

3

1 reference

29 July 2017

K Calder

4

1 reference

29 July 2017

G Ball

5

1 reference

29 July 2017

J Hanson

6

1 reference

29 July 2017

1 July 1999

1 reference

29 July 2017

1 reference

29 July 2017

10

1 reference

29 July 2017

857-859

1 reference

29 July 2017

7

1 reference

Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages.

29 July 2017

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008329821941

7 January 2021

Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008329821941

7 January 2021

The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008329821941

7 January 2021

Population-based norms for the Mini-Mental State Examination by age and educational level

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008329821941

7 January 2021

Thalidomide in leprosy reaction

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008329821941

7 January 2021

Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008329821941

7 January 2021

Clinical efficacy and safety of a novel controlled-release morphine suppository and subcutaneous morphine in cancer pain: a randomized evaluation

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008329821941

7 January 2021

Identifiers

DOI

10.1023/A:1008329821941

1 reference

29 July 2017

1 reference